Exponent Inc SEC Filings

Conestoga Capital Advisors filed Amendment No. 3 to a Schedule 13G reporting its beneficial ownership of 2,526,244 shares of Exponent Inc common stock, representing 5.06% of the outstanding class as of 12/31/2025. Conestoga has sole power to vote and dispose of 2,392,498 of these shares and no shared voting or dispositive power. The firm is classified as an investment adviser and certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Exponent Inc.

Exponent Inc. insider activity: President & CEO and director Catherine Corrigan reported exercising an incentive stock option for 7,872 shares of Exponent common stock on 12/16/2025 at an exercise price of $25.405 per share. After this transaction, she beneficially owns 92,006 shares of common stock directly. The derivative security reported is an incentive stock option covering 7,872 shares of common stock, with the option described as becoming exercisable in four equal annual installments, and 7,872 derivative securities remaining beneficially owned following the reported transaction.

Exponent Inc. President & CEO and director Catherine Corrigan reported an insider stock transaction. On 12/15/2025, she exercised a non-qualified stock option for 3,225 shares of common stock at an exercise price of $25.405 per share, increasing her directly held shares. On the same day, she sold 3,225 shares of common stock at a price of $70.7387 per share. After these transactions, she directly owned 84,134 shares of Exponent common stock and held 16,128 non-qualified stock options.

Exponent Inc. (EXPO) President & CEO and director Catherine Corrigan reported stock option exercises and related share sales. On 11/17/2025, she exercised non-qualified stock options for 3,225 shares at $25.405 and 2,380 shares at $29.05, converting them into common stock. She then sold 3,225 shares at $70.205 and 1,675 shares at an average price of $70.7387, with the filing noting that one sale was to cover the option exercise price and taxes. After these transactions, she directly owned 84,134 shares of Exponent common stock, and still held options for 19,353 and 19,038 shares that remain outstanding.

Exponent, Inc. (EXPO) reported higher Q3 results. Revenue rose to $147.1 million (up 8%) with revenues before reimbursements at $137.1 million (up 10%). Operating income increased to $29.0 million and net income reached $28.0 million, lifting diluted EPS to $0.55 from $0.50. Growth was driven by dispute-related work in energy, transportation, life sciences and construction, plus proactive risk management and regulatory consulting, partly offset by softer consumer electronics activity.

Cash and cash equivalents were $207.4 million as of October 3, 2025. For the first nine months, operating cash flow was $76.1 million, with $72.7 million used for share repurchases and $46.7 million for dividends. Subsequent to quarter-end, the Board approved a $0.30 per‑share dividend payable December 19, 2025, and authorized $100 million for additional share repurchases. Segment revenue grew across both Engineering & Other Scientific and Environmental & Health, with utilization modestly higher and billable hours up in the quarter.

Exponent, Inc. reported that it issued a press release covering results for the third quarter ended October 3, 2025. The company also announced a quarterly cash dividend of $0.30 per share, payable on December 19, 2025 to shareholders of record on December 5, 2025.

The Board authorized an additional $100 million for share repurchases, supplementing $21.6 million that was available for repurchase as of October 3, 2025. These actions return capital to shareholders through both dividends and buybacks, with timing and execution subject to market conditions and board discretion.

Exponent, Inc. (EXPO) reported insider activity by President & CEO and Director Catherine Corrigan on 10/15/2025. She exercised 3,226 options at $25.405 and 2,380 options at $29.05, then sold 3,226 shares at $66.84 and 1,704 shares at $66.7926. A footnote states the sale was to cover the option exercise price and taxes.

Following these transactions, she directly owned 83,429 shares. The options noted are non‑qualified stock options that vest in four equal annual installments.

Catherine Corrigan, President & CEO and director of Exponent Inc (EXPO), reported multiple transactions on 09/15/2025. She exercised two non-qualified stock option tranches: 2,380 options at a $29.05 exercise price and 3,226 options at a $25.405 exercise price, resulting in 5,606 shares acquired. Concurrently she sold 1,679 shares and separately sold 3,226 shares; one sale was described as to cover the option exercise price and taxes. After these trades her beneficial ownership is reported as 82,753 shares (direct). The Form 4 was signed on 09/16/2025 by an authorized filer.

Form 144 filed for EXPO reports a proposed sale tied to an option exercise and recent 10b5-1 plan sales. The filer exercised 4,905 common shares on 09/15/2025, paid in cash, with an aggregate market value reported as $343,595.25. The issuer's shares outstanding are listed as 50,501,135, and the proposed sale is to occur on 09/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing also discloses two 10b5-1 sales by Catherine Ford Corrigan on 08/14/2025 totaling 4,896 shares with combined gross proceeds of $348,042.61. The notice includes the standard attestation regarding material nonpublic information.